Lantern Pharma Announces Two Presentations at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting
June 17 2020 - 9:23AM
Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology
company focused on leveraging artificial intelligence (“A.I.”),
machine learning and genomic data to streamline the drug
development process and to identify the patients that will benefit
from its targeted oncology therapies, announced today that it will
make two presentations at the upcoming American Association for
Cancer Research (AACR) 2020 Virtual Annual Meeting, a meeting of
global leaders in cancer research taking place from June 22-24,
2020. They represent the Company’s first two presentations since
its IPO and subsequent listing on Nasdaq under the ticker symbol
‘LTRN.’
Each presentation will examine Lantern Pharma’s use of its A.I.
platform, RADR® (Response Algorithm for Drug Positioning and
Rescue), in the development of LP-184, one of three cancer drugs in
Lantern Pharma’s pipeline. The first abstract will focus on
LP-184’s unique features, including its nanomolar potency and its
activity in multi-drug resistant tumors, while the second abstract
will highlight Lantern Pharma’s use of machine learning,
specifically artificial neural networks, to pinpoint a genomic
signature most closely correlated with predicting response to
LP-184 across a range of solid tumors and central nervous system
(CNS) cancers. This signature is aimed at facilitating treatments
using LP-184 through genomics-guided therapy. LP-184 is a drug
candidate in preclinical development, which has shown early
indications of efficacy in solid tumors, as well as in glioblastoma
and CNS cancers with specific genetic and biomarker profiles.
RADR® is Lantern Pharma’s proprietary A.I. and machine learning
platform, which leverages over 275 million data points across more
than 140 drug-tumor interactions to predict the potential response
patients will have to Lantern Pharma’s cancer drug candidates and
to other drugs that it is reviewing and analyzing. Lantern Pharma
continues expanding RADR® with additional real-world data points,
tumor-specific data sets, proprietary experimental data and
validated drug-tumor models. The company is actively developing
additional collaborations and partnerships that will help expand
RADR® both in terms of datasets and functionality.
The AACR Annual Meeting highlights the work and discoveries of
the world’s leading cancer experts and researchers. In response to
the COVID-19 pandemic, this year’s meeting will be held virtually
and features speakers from leading healthcare institutions, cancer
research centers, large pharmaceutical companies and hospitals.
“We know that collaboration and the exchange of ideas among the
world’s most renowned oncology experts is key to combatting cancer
and improving patient outcomes,” said Panna Sharma, CEO of Lantern
Pharma. “Each year, the AACR annual meeting convenes leading voices
in cancer treatment from across the globe and is instrumental in
advancing cancer research and individual therapies like those
Lantern seeks to develop. We very much look forward to presenting
our knowledge and methodologies being used to advance LP-184, and
to applying the knowledge gained from the conference toward
advancing and ultimately commercializing our own pipeline of cancer
drugs, realizing long-term value for our shareholders.”
POSTER PRESENTATION DETAILS:
Poster One:
“LP-184, a molecule with nanomolar potency, exhibits strong
activity in lung cancers with KEAP1 and KRAS mutations,” presented
by Aditya Kulkarni, Ph.D.Poster Session Title: Novel Antitumor
Agents 1Abstract # 1464Poster Number: 4185
Poster Two:
“Machine learning-derived gene signature predicts strong
sensitivity of several solid tumors to the alkylating agent
LP-184,” presented by Umesh Kathad, M.S.Poster Session Title:
Machine LearningAbstract # 3305Poster Number: 2090
Full abstracts for the poster presentations can be found at the
AACR annual meeting website, www.aacr.org. They will also be
available after the presentations at the Company’s website -
www.lanternpharma.com.
About Lantern Pharma
Lantern Pharma is a clinical-stage biopharmaceutical company
innovating the repurposing, revitalization and development of
precision therapeutics in oncology. We leverage advances in machine
learning, genomics, and artificial intelligence by using a
proprietary A.I. platform to discover biomarker signatures that
help identify patients more likely to respond to our pipeline of
cancer therapeutics. Lantern’s focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, two in clinical stages and one in preclinical, focuses on
cancers that have unique and unmet clinical needs with a clearly
defined patient population. We believe that the use of machine
learning, genomics and computational methods can help accelerate
the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website at
www.lanternpharma.com or view company updates
@lanternpharma.
ContactKyle EvansPublic Relationsemail:
lantern@fischtankpr.com phone: 646-699-1414
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements in this press release
include, among other things, statements relating to: the potential
advantages of our RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of any of our drug
candidates; our strategic plans to expand the number of data points
that our RADR® platform can access and analyze; our research and
development efforts of our internal drug discovery programs and the
utilization of our RADR® platform to streamline the drug
development process; our intention to leverage artificial
intelligence, machine learning and genomic data to streamline the
drug development process and to identify patient populations that
would likely respond to a drug candidate; and our plans to discover
and develop drug candidates and to maximize their commercial
potential by advancing such drug candidates ourselves or in
collaboration with others. Additional information regarding the
risk factors to which we are subject is provided in greater detail
in our final prospectus for our initial public offering on June 10,
2020, on file with the Securities and Exchange Commission. You
may access our June 10, 2020 final prospectus under the investor
SEC filings tab of our website at www.lanternpharma.com or on the
SEC’s website at www.sec.gov. Given these risks and
uncertainties, we can give no assurances that our forward-looking
statements will prove to be accurate, or that any other results or
events projected or contemplated by our forward-looking statements
will in fact occur, and we caution investors not to place undue
reliance on these statements. All forward-looking statements in
this release represent our judgment as of the date hereof, and,
except as otherwise required by law, we disclaim any obligation to
update any forward-looking statements to conform the statement to
actual results or changes in our expectations.
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024